ArticleScientific reports2025
Association between blood eosinophil levels and prognosis in critically ill patients with different heart failure phenotypes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TSLP mitigates post-infarction myocardial remodeling by promoting eosinophil recruitment and inhibiting JAK1-STAT5-mediated ferroptosis.Apoptosis : an international journal on programmed cell death · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Heart failure (HF) is associated with poor prognosis. While various immune markers have been linked to HF outcomes, the relationship between eosinophils (EOS) and prognosis across different HF phenotypes remains unclear and controversial. In this study, we analyzed 2,677 HF patients from the Medical Information Mart for Intensive Care III (MIMIC-III) database, categorizing them into reduced ejection fraction (≤ 50%) and preserved ejection fraction (> 50%) groups. Multiple logistic regression, Kaplan-Meier survival curve estimation, Cox proportional hazards model, and restricted cubic splines were employed to assess the association between admission EOS and mortality. Subgroup analyses were conducted based on age, gender, sepsis, atrial fibrillation, hypertension and rheumatic and immunological diseases and mechanical ventilation. A total of 954 patients with heart failure with reduced ejection fraction (HFrEF) and 1723 patients with heart failure with preserved ejection fraction (HFpEF) were enrolled, with a female proportion of 37.84% and 56.88%, respectively. The median age of patients was 74.46 (IQR: 63.34-83.26) years and the median EOS was 0.09 (IQR: 0.04-0.20). Among these patients, in-hospital mortality was 14.5% (389 patients), and the overall 90-day mortality rate reached 27.12% (726 patients). There were no significant differences in EOS levels between the HFrEF and HFpEF groups (0.1 vs. 0.09, P = 0.154). After adjusting for confounders, multivariate logistic regression showed that higher EOS quartiles were associated with reduced in-hospital mortality in HFrEF patients, with quartile 3 (Q3) (OR 0.54, 95% CI 0.31-0.96, P = 0.035) and Q4 (OR 0.37, 95% CI 0.19-0.71, P = 0.003) showing significant protective effects compared with the lowest EOS quartile (Q1), while Q2 did not reach statistical significance (P = 0.931). Subgroup analyses yielded similar findings. Multivariate Cox regression demonstrated a reduced hazard ratio in Q4 (HR 0.64, 95% CI 0.44-0.94, P = 0.023) compared with Q1 in HFrEF patients. However, no significant association was observed between EOS and prognosis in HFpEF. Our findings indicated that higher EOS was associated with improved in-hospital and 90-day survival in ICU patients with HFrEF, but not in those with HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.